Anteris reports positive one-year results for DurAVR valve

Anteris Technologies has shared positive one-year results for its DurAVR Transcatheter Heart Valve (THV) system. The results were presented at a medical conference in Sydney on March 21, 2025. Dr. Rishi Puri presented data showing that patients treated with the DurAVR THV experienced strong hemodynamic performance after one year. Anteris Chief Medical Officer, Dr. Chris Meduri, highlighted that this valve showed zero prosthesis-patient mismatch in patients with small heart valves. This is significant because a mismatch can lead to valve failure and worsened health outcomes. A total of 65 patients have completed the primary endpoint measure at 30 days. The DurAVR THV system has shown consistent safety and efficacy throughout its clinical trials. This one-year data will be part of Anteris’ application to the U.S. FDA for approval to start a larger, pivotal study. The DurAVR THV is designed to treat aortic stenosis, a serious condition caused by the narrowing of the aortic valve. It is the first biomimetic valve, meaning it is designed to function like a healthy human aortic valve. The valve is made from a special tissue that helps prevent calcification and has been used safely in over 55,000 patients worldwide. Anteris is committed to advancing heart care with innovative technologies and aims to improve long-term outcomes for patients with structural heart disease.